Related Articles
OCT4‑positive circulating tumor cells may predict a poor prognosis in patients with metastatic castration‑resistant prostate cancer treated with abiraterone plus prednisone therapy
Clinical predictor of survival following docetaxel‑based chemotherapy
External beam radiation for the treatment of castration‑resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients
Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy
Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer